{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-040755","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.504400+00:00","generated_at":"2026-05-24T13:59:57.460006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Korro Bio reports FY2024 net loss $83.6M; cash $163.1M; KRRO-110 interim readout H2 2025","bullets":["Net loss $83.6M (vs $81.2M in 2023); R&D expenses $63.6M; G&A $30.5M.","Cash, cash equivalents $163.1M; runway into H2 2026 expected to fund KRRO-110 trial.","KRRO-110 Phase 1/2a REWRITE trial: completed dosing first two cohorts; no SAEs; interim data H2 2025.","FDA granted Orphan Drug Designation for KRRO-110 for AATD.","Collaboration revenue $2.3M from Novo Nordisk partnership; second development candidate expected end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-040755","json":"https://secwatch.observer/filing/0000950170-25-040755.json","markdown":"https://secwatch.observer/filing/0000950170-25-040755.md","text":"https://secwatch.observer/filing/0000950170-25-040755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017025040755/0000950170-25-040755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017025040755/krro-20250318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T13:59:57.460006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}